Apollo Care Recalls Semaglutide Vials Due to Particulate Matter
Apollo Care, LLC is recalling specific lots of Semaglutide 6.75mg vials because they contain nylon and silk-type particulate matter.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. Per the rubric, FDA Class II recalls are assigned a score of 4 (Severe), particularly when structural or contamination defects are present, even if specific hospitalization reports are not detailed in the provided text.
Plain-English summary
Apollo Care, LLC is voluntarily recalling 37,546 vials of Semaglutide 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vials. The recall is due to the presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material. The affected product is distributed nationwide within the U.S.
The recall covers specific lots with expiration dates ranging from November 2026 to May 2027. The NDC for the product is 71170-821-01. The agency has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Consumers and healthcare providers should stop using the affected vials and contact their healthcare provider or the recalling firm for further instructions. The source text does not report any specific illnesses or injuries associated with this recall.
The recalled product
- Product
- SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-821-01
- Manufacturer
- Apollo Care, LLC
- Category
- Drug — Injectable Medication
- Affected units
- 37,546
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot: C-017115
- Exp. 11/25/2026
- AC-017163
- Exp. 12/31/2026
- AC-017169
- AC-017170
- AC-017171
- AC-017230
- AC-017231
- Exp. 5/5/2027.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Apollo Care, LLC
See all →- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
Same hazard · particulate matter
See all →- ModerateIMAAVY Injection Recalled for Presence of Particulate Matter
FDA (Drugs) · 2026-10-14
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls Plum Administration Sets Due to Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
Similar recalls
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- HighSemaglutide 6 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighCompounded Semaglutide Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-09-11
- HighCompounded semaglutide vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide 2.5 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide Injection Recalled Due to Sterility Assurance Deficiency
FDA (Drugs) · 2022-11-09